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Abstract
Deoxyguanosine kinase (dGK) is an essential rate-limiting component of the mitochondrial purine nucleotide salvage
pathway, encoded by the nuclear gene encoding deoxyguanosine kinase (DGUOK). Mutations in DGUOK lead to mitochondrial
DNA (mtDNA) depletion typically in the liver and brain, causing a hepatocerebral phenotype. Previous work has shown that
in cultured DGUOK patient cells it is possible to rescue mtDNA depletion by increasing substrate amounts for dGK. In this
study we developed a mutant dguok zebrafish (Danio rerio) line using CRISPR/Cas9 mediated mutagenesis; dguok−/− fish have
significantly reduced mtDNA levels compared with wild-type (wt) fish. When supplemented with only one purine
nucleoside (dGuo), mtDNA copy number in both mutant and wt juvenile animals was significantly reduced, contrasting with
previous cell culture studies, possibly because of nucleotide pool imbalance. However, in adult dguok−/− fish we detected a
significant increase in liver mtDNA copy number when supplemented with both purine nucleosides. This study further
supports the idea that nucleoside supplementation has a potential therapeutic benefit in mtDNA depletion syndromes by
substrate enhancement of the purine nucleoside salvage pathway and might improve the liver pathology in patients.
Introduction
Mitochondrial DNA depletion syndromes (MDS) are a heteroge-
neous group of autosomal recessive disorders characterized by
a severe reduction in mitochondrial DNA (mtDNA) copy number
in different tissues without mutations in the mtDNA itself (1).
The initial clinical presentation tends to be organ specific,
manifesting in tissues that have a high energy demand such
as skeletal muscle, the central nervous system (CNS) and liver,
often progressing to severe multisystem disorders (2–4). Reduc-
tion of mtDNA leads to the inability to maintain the essential
respiratory chain (RC) complexes, resulting in impairment in
ATP synthesis, and tissues are unable to function normally (5–7).
Changes causing these clinically very heterogeneous diseases
are autosomal recessive mutations in at least 15 nuclear genes
involved in nuclear-mitochondrial intergenomic signalling
pathways. The phenotypes for these disorders can be quite
varied from isolated ophthalmoplegia to other tissue-specific
or multi-system diseases. The human mitochondrial genome is
replicated by polymerase gamma (POLG) in concert with other
components of themitochondrial replicationmachinery (TWNK,
SLC25A4, MGME1, TFAM, DNA2, RNASEH1) (1). MtDNA depletion
in these conditions may be associated with multiple mtDNA
deletions and point mutations (POLG, TWNK, SLC25A4, MGME1,
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TFAM). Some genes affecting mtDNA replication may result only
in mtDNA deletions or point mutations in adults (POLG2, DNA2,
RNASEH1), and the inheritance pattern of these genes may be
autosomal dominant or recessive (1).
The balanced supply of nucleotides is critically important
for DNA integrity. Nucleotide levels are maintained by de novo
synthesis or by salvage pathways (8). Mutations in nuclear
genes involved in the maintenance and supply of mitochondrial
nucleotide pools have been associated with MDS with different
tissue-specific clinical manifestations (TK2, DGUOK, RRM2B,
TYMP, SUCLA2, SUCLG1). Early-onset organ-specific autosomal
recessive syndromes due to mutations in genes with miscella-
neous pathomechanism (FBXL4,GFER,ABAT,AGK, SLC25A21)may
also result in mtDNA depletion. Furthermore, defects of mtDNA
dynamics (OPA1, MFN2, DRP1) and quality control (SPG7, AFG3L2)
can also affect the amount and quality of mtDNA, however,
these diseases are more common causes of mtDNA deletions
than depletion of mtDNA (1).
Two genes of particular interest are DGUOK and TK2. DGUOK
encodes deoxyguanosine kinase (dGK), an important anabolic
enzyme involved in the maintenance of mitochondrial purine
deoxyribonucleotide triphosphate (dNTP) pools. dGK is the
first rate-limiting step of the mitochondrial purine nucleotide
salvage pathway, phosphorylating deoxyadenosine (dAdo) and
deoxyguanosine (dGuo) into deoxyadenosine monophosphate
(dAMP) and deoxyguanosine monophosphate (dGMP), respec-
tively (4). In addition, TK2, which encodes thymidine kinase 2
(TK2), has a similar role in maintaining the dNTP pools. TK2 is
the first step of the mitochondrial pyrimidine salvage pathway,
acting in much the same way as dGK, the difference being that
it phosphorylates deoxycytidine (dC) and deoxythymidine (dT)
into their corresponding dNMPs, deoxycytidine monophosphate
(dCMP) and deoxythymidine monophosphate (dTMP) (9). A
noteworthy difference is that mutations in DGUOK and TK2
present clinically as two distinct phenotypes (10). DGUOK
mutations typically have a hepatocerebral presentation with
mtDNA depletion; however, recently chronic progressive exter-
nal ophthalmoparesis, mitochondrial myopathy, Parkinsonism
andmultiple mtDNA deletions were also reported in association
with recessive DGUOK mutations in some patients (11), while
mutations in TK2 have a primarily myopathic manifestation.
The involvement of the nervous system often complicates the
clinical course of the infantile-onset form while extraocular
muscle and facial involvement are characteristics of the late-
onset form (12).
The nucleotide salvage pathway recycles free bases from old
RNA and DNA in both the mitochondria and cytosol into dNTPs
to maintain the nucleotide pools needed for DNA replication.
This contrasts with the de novo nucleotide synthesis pathway,
which occurs only in the cytosol of replicating cells (13). As
mtDNA replication is independent of the cell cycle, the salvage
pathway is essential in maintaining the mitochondrial dNTP
pool in post-mitotic tissue as well as in dividing cells (14–16).
Previously it has been shown that it is possible to rescue
mtDNA depletion in DGUOK patient myotubes with supplemen-
tation of dAMP and dGMP (17). dGK-deficient cell lines (p1,
p2) showed a highly significant (P < 0.01) increase in mtDNA
copy number, reaching normal levels when supplemented with
200 μm dAMP/dGMP or with 400 μm dAMP/dGMP.
A more recent study has shown that mtDNA depletion is
rescued by addition of 50 μm dGuo alone to quiescent fibroblast
culture and that dAdo addition does not have any detectable
effect (18). Supplementation with dGMP also rescued mtDNA
depletion. These results indicate that dNMPs are rapidly dephos-
phorylated in cell culture medium and strongly suggest that
dephosphorylationmainly occurs extracellularly.They also illus-
trate that dGuo is as effective as dGMP for preventing mtDNA
depletion in dGK-deficient cells.
Further to this it has been shown that supplementa-
tion of deoxythymidine and deoxycytidine monophosphates
(dTMP + dCMP) in a murine MDS model with a Tk2 H126N
(Tk2−/−) knock-inmutation,also showed tissue-specific increases
in mtDNA copy number, disease onset delay as well as
significantly prolonging the animals’ life span, suggesting
bypassing the defective enzyme is an effective therapeutic
approach (19). Subsequentworkwith the samemodel has shown
that supplementation with deoxynucleosides, dC and dT also
has the same effect, suggesting that substrate enhancement
may be enough to delay the progression of MDS in patients (9).
However, no mouse model has been produced for DGUOK
mutations yet. Zebrafish (Danio rerio) are a good candidate for
a disease model as they are routinely used in drug discovery
and validation for a variety of neurological and neuromuscular
diseases (20,21). Their rapid development, transparency during
early life stages and the possibility of administering chemical
compounds to tank water make them suitable. The growing use
of Crispr/Cas9 technology in zebrafish has made the generation
of mutants rapid and reliable and as no DGUOK knockout mouse
was currently available for supplementation studies, we decided
to generate a zebrafish dguokmutant strain, and use it to test the
substrate enhancement therapy.
Results
Generating a mutant zebrafish line for dguok
One paralog of the human DGUOK gene was located in the
zebrafish genome on chromosome 5. The zebrafish dguok gene
has 7 exons and encodes a protein of 269 amino acids. The amino
acid sequence of the zebrafish DGK protein is 55% identical and
72% similar to its human counterpart (Supplementary Material,
Fig. S1; accession number NP 001093561.1).
To generate a zebrafish mutant line for dguok by using
CRISPR/Cas9, we selected two sgRNA target sequences in exon
3 (Supplementary Material, Fig. S1A). We aimed to introduce the
mutation as close to the N-terminus of the protein as possible
in order to avoid residual enzyme activity to still be present
in the mutants. We avoided targeting exon 1, as an alternative
translation start might be chosen by the cell, and in exon 2
no sgRNA sequences with high activity and low off-target score
could be found. Both selected sgRNA targeting exon 3 produced a
range of in frame and frameshift indel mutations. The mutation
we chose for our stablemutant line was c.351 352delGCinsCCTG
(Supplementary Material, Fig. S1B). The mutation causes a
frameshift and induces a premature stop codon after 28
missense amino acids (Supplementary Material, Fig. S1E). In
order to verify whether the mutated dguokmRNA is degraded by
nonsense mediated decay, we analysed dguok transcripts from
one homozygous mutant adult fish. We were able to amplify
and sequence full-length dguok transcripts from the liver of the
mutant and a wild-type (wt) control. The transcript amplified
from the mutant carried the mutation c.351 352delGCinsCCTG
homozygously as on genomic DNA (gDNA) level (Supplementary
Material, Fig. S1D); no additional modifications such as skipping
of exonic sequences or insertion of intronic sequences were
detected. Because of the lack of a suitable antibody we were not
able to check for the presence of a protein product by western
blot. The C-terminal half of the enzyme is well conserved among
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Figure 1. Survival of dguok mutant zebrafish. dguok−/− zebrafish do not exhibit
decreased survival initially; the proportion of homozygousmutants among adult
population up to the age of 9months is still close to the expectedMendelian ratio
of 25%. The proportion of homozygous and heterozygous fish was determined at
the ages of 2, 3, 5 wpf and at the age of 6–9 months. Total numbers of genotyped
fish were 159 at 2 wpf, 117 at 3 wpf, 57 at 5 wpf and 146 adult fish.
species and contains a part of the active domain of the enzyme
(structure in 22). Therefore we expect that even if the mutated
dguok mRNA is translated into a protein, this protein would not
have the enzymatic activity of dGK.
Characterization of the mutant phenotype
Surprisingly, embryos and larvae homozygous for dguok
c.351 352delGCinsCCTG did not display any abnormal pheno-
type; we did not observe any abnormal morphological traits or
swimming defects. When genotyping all offspring of different
lays, the mutation was detected at the expected Mendelian rate
of 25%, indicating that homozygous mutant animals do not
die prematurely during early stages of development (Fig. 1). We
attempted to see if blocking the uptake of dNTPs from the cytosol
into mitochondria by inhibiting the equilibrative nucleoside
transporter 1 (ENT1) with various doses of S-(4-Nitrobenzyl)-
6-thioinosine can trigger the appearance of morphological
abnormalities in the first 5 days of life. However, we did
not observe any morphological abnormalities in either wt,
heterozygous or homozygous fish larvae (data not shown).
There was a high variability in terms of size and weight
among the mutant animals starting from the age of 3 weeks
onwards, but we observed the same variability also among wt
controls and heterozygous animals; there was no difference
among the groups (Supplementary Material, Fig. S2A). A smaller
size was not linked to the homozygous mutant genotype.
In fact, homozygous animals survived into adulthood, and
the proportion of homozygous mutants among adult F2 off-
spring was still ∼25% until the age of 9 months (Fig. 1). Adult
homozygous fish are indistinguishable from their wt siblings in
terms of appearance and size (SupplementaryMaterial, Fig. S2B);
they swim normally in the tanks. However, we observed reduced
fertility among homozygous fish; we were not able to obtain
offspring from a cross of two homozygous adults. On dissection
we detected reduced number of eggs in the female fish. At the
age of ∼10 months, homozygous adults started to struggle to
swim normally and maintain their position in the water. This
led to them being culled for animal welfare reasons. By 1 year of
age all the homozygous adults had died.
Gene expression analysis in homozygous mutants
We analysed transcript levels of dguok, tk2 and other transcripts
encoding mitochondrial proteins in adult wt and homozygous
mutant fish in brain, muscle and liver (Supplementary Material,
Fig. S3). We designed two primer pairs to amplify dguok, one
pair located 5′ and the second pair located 3′ of the mutation
in order to investigate nonsense mediated decay of the mutated
transcript quantitatively. We noticed variability between indi-
vidual fish also among the tested wt animals, especially in the
liver; furthermore, transcript levels also varied between tissues.
One of the two wt animals had much higher dguok mRNA levels
than the other wt animal and the two mutants. Transcripts
of dguok were detected in all three tissues in the mutant fish,
thus excluding relevant nonsensemediated decay of themutant
mRNA (Supplementary Material, Fig. S3). In brain, levels of most
transcripts were slightly downregulated in mutants, whereas
in tail muscle the same transcripts were slightly increased in
mutants. No general trend of up- or down-regulation of the
analysed mitochondrial transcripts was observed.
mtDNA content analysis
As DGUOK mutations cause mtDNA depletion in humans, we
measured relative mtDNA to nDNA levels in mutant and wt
fish. At the age of 3 weeks we observed a significant 2-fold
reduction ofmtDNA levels in homozygousmutants. The 3-week-
old fish appear normal despite having only 50% of the wt levels
of mtDNA. The mtDNA amount in heterozygous animals did not
differ from the wt (Fig. 2A, 117 fish tested in total).
At the age of 5 weeks we measured the mtDNA levels in
the tail (skeletal muscle tissue) and in the head (brain tissue)
of wt, heterozygous and homozygous mutant fish (Fig. 2B, 57
fish tested in total). The difference between wt and homozygous
animals was increased compared with the difference detected
at 3 wpf, especially in brain tissue. Heterozygous animals had
similarmtDNA levels aswt animals.As some of the patientswith
DGUOK mutations were reported to have mtDNA deletions (11),
we also performed long-range polymerase chain reaction (PCR)
to amplify the mtDNA in mutant fish but detected no mtDNA
deletions. In adult fish we detected a 4-fold higher mtDNA
amount in wt compared with homozygous adults in tail muscle
and brain (see Fig. 5, untreated fish). The mtDNA levels in adult
mutants stayed constant up to the time of death. In fish that had
to be culled because of the loss of the ability to swim no dip in
the mtDNA copy number was observed before death.
Nucleoside supplementation
Previously it has been shown in cultured cells that supple-
mentation with 50 μm deoxyguanosine alone was sufficient to
significantly increase the mtDNA copy number in fibroblasts
frompatientswithDGUOKmutations (18). Thereforewe used the
same concentration for supplementation in our dguok mutant
zebrafish. We treated offspring of a cross of dguok heterozy-
gous parents (offspring should be a mixture of wt, heterozy-
gous and homozygous animals) with 50 μm dGuo from 0 hpf
onwards for 2 weeks. Initially we chose this time point, as by
this age a difference between mtDNA levels in wt and mutant
fish should be detectable (see Fig. 2). After 2 weeks of supple-
mentation, the juvenile fish were culled, gDNA was isolated,
the fish were genotyped and mtDNA levels were determined in
wt and homozygous animals only (N: between 25 and 34 fish
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Figure 2. The mtDNA amount is significantly reduced in juvenile dguok−/−
zebrafish. The mtDNA levels in heterozygous mutants were similar to the wt.
The relative amounts of mtDNA were calculated as mean Ct values of the
difference in cycle threshold (Ct) of the mitochondrial encoded gene ND1 minus
the Ct of the nuclear gene ef1α. (A) mtDNA levels at 3 weeks of age (DNA
isolated from entire fish). (B) mtDNA levels at 5 weeks of age in head/CNS and
tail/skeletal muscle. The difference between wt and homozygous fish becomes
more pronounced in the CNS with increased age.
per group). Although the numbers of animals in each treatment
group were not high, we observed that in the zebrafish animal
model, in contrast to cultured patient fibroblasts, dGuo alone sig-
nificantly reduced the copy number in mutant and wt animals
and therefore the supplementation experiment with dGuo alone
was stopped (Fig. 3).
Next, we decided to supplement the fish with a combina-
tion of both dAdo and dGuo for 2 weeks, starting again 0 hpf
as previously. This time, the mtDNA levels did not decrease
but we could not detect a significant increase either (Fig. 4). In
comparison to the difference in mtDNA content seen earlier in
Figure 3 after the single nucleoside treatment there was a lack of
difference now in Figure 4 between treated and untreated fish.
At this age, however, the mtDNA to nuclear DNA ratio difference
between wt and homozygous mutants is significant but not
very pronounced, and the variability between individual fish is
relatively high (see Fig. 2).We suspected that this high variability
among individual fish may obscure a small increase in mtDNA
levels caused by the nucleoside supplementation.
As we had noticed in preliminary experiments that the dif-
ference in mtDNA levels between dguokmutant and wt fish was
Figure 3. Supplementation with deoxyguanosine alone reduces mtDNA levels.
The mtDNA amount is significantly reduced in wt and homozygous mutant
juvenile fish by a 2week treatmentwith 50 μmdeoxyguanosine alone (totalN = 25
homozygous, 34 wt animals, P < 0.05 for wt and P < 0.01 for homozygous fish,
respectively).
Figure 4. Sup plementation with deoxyguanosine and deoxyadenosine in juve-
nile fish. MtDNA levels do not change significantly in wt and homozygous
mutant juvenile fish after a 2 week treatment with 50 μm deoxyguanosine and
50 μm deoxyadenosine (total number of untreated/treated animals:N = 26 and 32
homozygous, 31 and 33 wt animals). The differences between the homozygous
untreated and treated group, as well as between the wt untreated and treated
group, are not statistically significant.
more pronounced in adult fish,we next tried if supplementation
with dGuo and dAdo in adult fish can lead to a restoration of
the mtDNA levels. We treated adult wt and dguok homozygous
fish with 50 μm dAdo and dGuo for 3 weeks. After the supple-
mentation period we analysed mtDNA levels in the head (brain),
tail (skeletal muscle) and the liver of treated and untreated fish.
We detected a slight but significant increase in mtDNA levels in
the liver of supplementedmutant fish but not in skeletal muscle
or brain (Fig. 5). Difference in mtDNA levels between untreated
wt and homozygous animals is most pronounced in the CNS (4-
fold decrease, Fig. 5). In addition, we also analysed the protein
level of mitochondrial RC complexes by western blot in treated
and untreated adult fish (Supplementary Material, Fig. S4). We
observed a slight increase in the amount of porin/VDAC1 and
complex 4 and 5 but the increase was not significant. This might
be due to the highly variable protein levels between individual
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Figure 5. mtDNA levels inwt andhomozygous adult fish after a 3week treatment
with 50 μm deoxyguanosine and 50 μm deoxyadenosine. Forty adult fish between
the ages of 6 and 9 months were treated (10 fish per category); skeletal muscle,
liver andheadswere dissected after the treatment period for DNAextraction.The
treatment induced a significant increase of mtDNA levels in the livers of mutant
animals (P< 0.05); the mtDNA levels also increased in the livers of treated wt
animals but the difference was not significant. Differences between untreated
wt and untreated homozygous mutants were statistically significant in all three
tissues (P < 0.0001, data not shown).
fish. We could not detect any mtDNA deletions in either the
treated or the untreated adult fish.
Discussion
Animal models for MDS are essential for testing novel com-
pounds and assessingwhether they could be suitable for treating
patients. Previous work from other laboratories suggested that
good strategies for restoringmitochondrial dNTP pools are either
bypassing the enzymedefect (17,19,23) or by increasing substrate
availability (substrate enhancement 9,18). So far, the only in
vivo work proving the efficacy of either dNMP or deoxynucle-
oside supplementation was performed in Tk2 H126N knock-
in mice (9,19) and focused on the pyrimidine nucleotide half
of the mitochondrial dNTP metabolism. To our knowledge, no
mouse model for defects of the purine phosphorylating enzyme
dGK has been published yet. Therefore, we decided to create
a zebrafish model and investigate whether supplementation
of the substrate nucleosides reverses the depletion of mtDNA
levels in the mutants, as it was previously shown in vitro. We
established a dguok mutant zebrafish line carrying a frameshift
mutation in exon 3 leading to a premature translation termina-
tion. Although we were not able to verify protein expression, we
expect that no fully functional dGK enzyme was expressed in
the homozygous mutants. In contrast to humans with DGUOK
mutations, the dGK-deficient zebrafish had lower mtDNA levels
than their wt siblings but displayed no visible phenotype up
to the age of ∼10 months. mtDNA levels were at 50% of the
wt levels in juvenile dguok−/− fish, dropped further to ∼25%
in adulthood. MtDNA levels showed tissue-specific differences
and reflecting the clinical presentation in patients, lower levels
were detected in brain and liver tissue. However, this decrease
of mtDNA amounts did not cause a visible phenotype in the
homozygous mutants. One reason for this could be compen-
sation by the cytoplasmic enzyme deoxycytidine kinase (dCK).
dCK phosphorylates deoxyribonucleosides and nucleoside in the
cytosol as part of the cytosolic salvage pathway. In cells that
are dividing and replicating their nuclear DNA, nucleotides can
be imported from cytosol into mitochondria (reviewed in 8).
Zebrafish embryos and larvae grow fast and have rapid cell
division, especially during the first days of development (24).
This could ensure that enough dNTPs can be imported into
mitochondria during this period. Another reason for the lack
of phenotype in the dguok mutant fish during the early period
of life could be the fact that there is no substantial increase
in mtDNA copy number in the first 5 days of life in zebrafish
embryos (25). Combined with the import of nucleotides from the
cytosol it might explain why zebrafish compensate better for
dGK deficiency than humans. All dguok−/− fish eventually died
or had to be culled for animal welfare reasons before the age of
1 year. The cause of the sudden deterioration of health or death
remained unclear.
No zebrafish model has been described yet for the other
enzyme of the mitochondrial salvage pathway, TK2. A zebrafish
model for POLG mutations developed a much more severe phe-
notype than our dguok−/− fish with mtDNA depletion, smaller
body size and death around the age of 4 weeks (26).
We attempted to trigger a phenotype in the dguok−/− embryos
by exposing offspring of an incross of dguok+/− parents to S-(4-
Nitrobenzyl)-6-thioinosine, an inhibitor of equilibrative nucleo-
side transporters (ENTs), up to the age of 5 dpf. Human ENT1
is localized on the cell surface as well as on the mitochondrial
membrane and facilitates the uptake of nucleosides into mito-
chondria (27). We intended to block the uptake of nucleosides
from the cytosol into mitochondria of the dguok−/− fish and
thereby force the cells to rely more on their mitochondrial dNTP
pools and thus on the enzymatic activity of dGK. However, no
morphological phenotype was observed in the dguok−/− fish as a
consequence of ENT inhibition. It may be possible though that S-
(4-Nitrobenzyl)-6-thioinosine is not taken up from the water by
zebrafish embryos or does not inhibit the zebrafish transporters
at the concentrations used by us, as to our knowledge S-(4-
Nitrobenzyl)-6-thioinosine has not been tested in zebrafish yet.
Although the dguok mutant fish did not display any visible
morphological changes, the decreasedmtDNA levels provided us
with an experimental readout to assess the efficacy of chemical
compounds as potential treatment for MDS. First, we attempted
to increase the mtDNA levels in the dguokmutant fish by adding
dGuo alone similar to the experiments performed in cell culture
(18). Furthermore, studies in dGK-deficient cells showed that
mainly dGTP levels were affected by DGUOK mutations (28) and
were critical for the maintenance of mtDNA levels, suggest-
ing that increasing the availability of dGuo could be enough
to restore mtDNA copy number. However, we noticed that, in
contrast to cultured fibroblasts, the mtDNA levels in zebrafish
dropped during the supplementation with dGuo alone. It may
be that increasing the concentration of just one of the substrate
nucleosides introduces an imbalance into the dNTP pool and
thereby interfereswithmtDNA replication and as a consequence
reduces the mtDNA copy number. This result prompted us to
supplement the dguokmutant fish with both purine nucleosides
instead. In this experiment we did not detect any drop ofmtDNA
levels in juvenile fish; however, we were not able to obtain
a significant increase of mtDNA levels either. As the mtDNA
levels varied considerably between individual animals, it might
be likely that small changes are difficult to detect.
As the difference in mtDNA levels between wt and dguok
deficient fish ismuchmore pronounced in adult fish,we decided
to supplement adult fish with both purine nucleosides. After
3 weeks of supplementation we detected an increase of mtDNA
levels but only in the liver. MtDNA levels in tail skeletal muscle
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and brain did not change. Longer treatment of adult fish or
life-long supplementation from 0 hpf onwards might increase
mtDNA level also in other tissues in the dguok−/− fish or might
be able to extend the life span of themutants. The tissue-specific
effect of the substrate enhancement therapy has previously been
shown also in the mouse model of Tk2 deficiency (9). Similar to
our results, deoxycytosine and deoxythmidine supplementation
in the Tk2 mutant mouse led to a stronger increase of mtDNA
levels in liver (and other internal organs that we did not study
in zebrafish) compared with brain (9). In the Tk2 mutant mice,
however, in contrast to the dguok−/− fish, mtDNA depletion was
partially rescued in skeletal muscle. Purine nucleotides may be
less stable than pyrimidines, and therefore higher doses may be
required in dGK deficiency in order to obtain a recovery from
mtDNA depletion. In addition, it has previously been shown that
in mice and rats, mitochondrial turnover is faster in the liver
compared with tissues such as brain and muscle, suggesting
that this may be a factor in why we see the greatest change in
mtDNA in the liver with a short treatment (29,30). The tissue-
specific differences in the efficiency of the rescue of the mtDNA
depletion need to be kept in mind if nucleoside supplementa-
tion will be tested in humans in the future. However, as the
DGUOK patients mainly present with a hepatocerebral pheno-
type, a rescue of the mtDNA depletion in liver might still be
beneficial.
In summary, zebrafish are a good in vivo model to study the
effect of nucleoside supplementation in mtDNA maintenance
diseases and may be further investigated. Other mtDNA main-
tenance defects might require supplementation with all four
nucleosides in order to avoid dNTP pool imbalances. Based on
our results, dosing nucleosides needs to be finely tuned and
optimized, and results obtained in vitro in cell culture may not
always be transferable to animal models.
Materials and Methods
Zebrafish husbandry
All zebrafish (D. rerio) used were of the golden background and
were maintained according to standard protocol (24). All exper-
iments were conducted in-line with the UK Home Office regu-
lations with approval from the local Named Animal Care and
Welfare Officers.
sgRNA synthesis
The Crisprscan website (31) was used to identify target sites in
exon 3 of the dguok gene in zebrafish (Genbank accession num-
ber for the sequence of zebrafish dguok: NM 001100091). sgRNA
was produced through a cloning-free method by following a pre-
viously published protocol (32,33). The two selected guide RNA
target sequences were gG18NGG-70AGGTGTAGGACCAGCGCTTC
GGG and gG18NGG-86 CGCAGGAGTGTGTCCGGCAGCGG. The
sgRNA was diluted to 300 ng/μl with 2 μm Cas9 protein (New
England Biolabs Ltd, Hitchin, UK), 2 M KCl and 0.05% phenol
red and heated to 37◦C for 5 min. Embryos were injected at
the one cell stage with 1 nl of the sgRNA/Cas9 protein mixture.
Injected F0 fish were raised to adulthood and then outcrossed
with golden fish in order to check for germline transmission
of the mutation. Offspring of this outcross were raised as F1
generation and genotyped by fin clipping at the age of 3 months.
Extraction of gDNA from zebrafish
gDNA was extracted and purified using the Qiagen Blood and
Tissue kit (Qiagen, Hilden, Germany) with EconoSpin All-In-One
Mini Spin Columns (Epoch Life Sciences Inc., Missouri City, TX,
USA). DNA concentrations weremeasuredwith a Nanodrop 2000
spectrophotometer (Thermo Scientific).
Zebrafish genotyping
dguok exon 3 was amplified from gDNA via PCR with primers
designed to cover the region of interest (see primer table). PCR
product was digested at 60◦C with the restriction enzyme BstAPI
(New England Biolabs) that cuts the wt sequence into two frag-
ments and leaves the homozygous sequence uncut.
Measurement of mtDNA levels in zebrafish
MtDNA levels were determined using qPCR following the pro-
tocol previously published by Rahn et al. (26) using primers for a
mitochondrial gene, NADH dehydrogenase-1(ND1) and a nuclear
gene, elongation factor 1 alpha (see primer table). The relative
amount of mtDNA was calculated at the Ct value difference of
the two genes.All sampleswere run in triplicate. Statistical anal-
ysis (Analysis of variance, t-test) was performed in the GraphPad
Prism software.
Long-range PCR in zebrafish
Long-range PCR assays were performed in order to determine
the presence of deletions in the zebrafish mtDNA. Primers zf
mtDNA 6395 fwd and zfmtDNA 15929 rev were used to amplify a
fragment of the zebrafishmtDNA corresponding to the fragment
containing the most common mtDNA deletions detected in
patients. PrimeSTAR GXL polymerase (Takara Bio Europe, Saint-
Germain-en-Laye, France) and 100 μg template DNA were used
for the long-range PCR; the primer sequences are listed in the
primer table.
RNA isolation, Reverse transcription polymerase chain
reaction (RT-PCR) and gene expression analysis in
zebrafish
Trizol® (ThermoFisher, Waltham, MA, USA) was used to isolate
RNA from adult zebrafish tail tissue following the manufac-
turer’s instructions. Residual gDNA was removed by incubating
the RNA with DNAseI (DNA-freeTM DNA Removal Kit, Ambion,
Waltham,MA,USA). TheHigh-Capacity cDNAReverse Transcrip-
tion Kit (Applied Biosystems, Waltham, MA, USA) was used to
synthesize cDNA from the isolated RNA following the man-
ufacturer’s instructions; 2 μg total RNA was used for reverse
transcription. RT-PCR was performed using the primers listed in
the table. quantitative reverse transcription polymerase chain
reaction (qRT-PCR) (Biorad Iight-cycler equipped with a MyIQ
detection system) was performed in triplicates (technical repli-
cates with the same cDNA) using the iTaqTM Universal SYBR®
Green Supermix (Bio-Rad Laboratories Ltd, Hercules, CA, USA)
and the primer pairs listed in the primer table. All primer pairs
except the dguok primers have been published previously (25,26).
Beta-actin was used as housekeeping gene to normalize gene
expression.
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Nucleoside supplementation
Two different nucleoside supplementation treatments were
performed. The first consisted of 50 μm 2
′
-Deoxyguanosine
monohydrate (D7145, Sigma-Aldrich, St. Louis, MO, USA)
dissolved in system water. The second consisted of both 50 μm
2′-Deoxyguanosine monohydrate (D7145, Sigma-Aldrich, St.
Louis, MO, USA) and 50 μm 2′-Deoxyadenosine monohydrate
(D7400, Sigma-Aldrich, St. Louis, MO, USA) with 5 μm of EHNA
hydrochloride (E114,Sigma-Aldrich,St. Louis,MO,USA) dissolved
in system water. EHNA hydrochloride was added to inhibit
the breakdown of deoxyadenosine by the enzyme adenosine
deaminase.
Nucleoside supplementation in juvenile zebrafish
Heterozygous (+/−) dguok mutants (c.351 352delGCinsCCTG)
were group spawned and embryos collected in petri dishes.
Embryos were either supplemented with nucleoside solution or
system water (control). The water was changed daily, reapplying
the treatment, and any dead embryos were removed. At 5 dpf
embryos were placed into 1 litre plastic spawning tanks and
water changed every 48 h and fish fed three times daily. At 2 wpf
the embryos were culled and collected in accordance with the
home office guidelines via a schedule 1 method.
Nucleoside supplementation in adult fish
Adult homozygous (−/−) dguokmutants (c.351 352delGCinsCCTG)
were placed in 2 litre tanks, with treatment solution (n = 5)
or with system water (control) (n = 5). Wt (control) fish were
placed in two tanks, one with treatment (n = 5) and one
with system water (n = 5). Adults were only supplemented
with both 50 μm deoxyguanosine and deoxyadenosine (and
EHNA). The water was changed every 48 h, treatment reap-
plied and fish fed three times daily, twice with dry flake
(Tetra, Blacksburg, VA, USA) and once with brine shrimp
(Artemia). After 3 weeks, the fish were collected and culled
in accordance with the UK Home Office guidelines via a
schedule 1 method. Immediately after the fish had been culled
they were dissected and tail muscle, liver and heads were
collected and frozen before analysis. The health of the fish
was monitored throughout the treatment. Supplementation of
adult fish was performed twice with a total of 10 animals per
group.
Immunoblotting
Muscle tissue from the tail of adult zebrafish were homogenized
in RIPA buffer with protease inhibitors. A total protein of 30 μg
were loaded on 4–12% SDS–polyacrylamide gels (NuPAGETM 4–
12% Bis-Tris Protein Gels, ThermoFisher, Waltham, MA, USA),
transferred to a PVDF membrane with an iBlot®2 PVDF Mini
transfer stack (ThermoFisher, Waltham, MA, USA) and subse-
quently probedwith antibodies recognizingNDUFA9 (Abcamplc,
Cambridge, UK ab14713, 1:500), MTCO1 (Abcam plc, Cambridge,
UK ab14705, 1:500), porin/VDAC1 (Abcam plc, Cambridge, UK
ab15895, 1:1000), ATP5A (Abcam plc, Cambridge, UK ab14748,
1:1000), GAPDH (Anti-GAPDH (14C10) rabbit mAb #2118 Cell Sig-
nalling Technology,Danvers,MA,USA) or β-actin (Sigma-Aldrich,
St. Louis,MO,USAA1978, 1:2000). Quantification of protein levels
was done using the Fiji (ImageJ) software.
ENT1 inhibition
Heterozygous (+/−) dguok mutants (c.351 352delGCinsCCTG)
were spawned and embryos collected. Embryos (n = 100) were
exposed to a range of concentrations (1, 5, 10 and 50 μm) of
S-(4-Nitrobenzyl)-6-thioinosine (Sigma-Aldrich, St. Louis, MO,
USA, N2255) or DMSO (D8418, Sigma-Aldrich, St. Louis, MO, USA)
(vehicle control) at 1 dpf. The larvae were monitored for the first
5 dpf for any phenotypic abnormalities and treatment solution
was reapplied every 48 hpf. At 5 dpf a sample of embryos (n = 16)
was collected from each treatment group and genotyped as
described above. We subsequently repeated the treatment once
with treatment concentrations of 10 μm, 50 μm S-(4-Nitrobenzyl)-
6-thioinosine or DMSO starting with embryos at 0 dpf.
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